Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the sixteen research firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $381.00.
COR has been the topic of several research reports. JPMorgan Chase & Co. raised their price objective on Cencora from $390.00 to $413.00 and gave the stock an "overweight" rating in a report on Tuesday, November 10th. Evercore reissued an "outperform" rating and issued a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Robert W. Baird boosted their target price on Cencora from $373.00 to $375.00 and gave the company an "outperform" rating in a report on Thursday, October 22nd. Barclays upped their target price on Cencora from $350.00 to $415.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Citigroup restated a "buy" rating on shares of Cencora in a research note on Thursday, August 6th.
Get Our Latest Stock Report on Cencora
Insider Buying and Selling at Cencora
In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company's stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company's stock.
Institutional Trading of Cencora
Several institutional investors and hedge funds have recently bought and sold shares of COR. BlackRock Inc. purchased a new position in Cencora during the 2nd quarter worth $5,154,136,000. Boston Partners increased its stake in Cencora by 7.8% in the third quarter. Boston Partners now owns 5,247,872 shares of the company's stock valued at $1,578,543,000 after purchasing an additional 379,090 shares during the period. Bank of America Corp DE increased its stake in Cencora by 6.9% in the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company's stock valued at $1,300,033,000 after purchasing an additional 267,318 shares during the period. Amundi raised its holdings in shares of Cencora by 43.5% in the second quarter. Amundi now owns 2,229,326 shares of the company's stock valued at $630,855,000 after buying an additional 676,066 shares during the last quarter. Finally, Carmignac Gestion raised its holdings in shares of Cencora by 58.7% in the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company's stock valued at $494,463,000 after buying an additional 646,112 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.
Cencora Trading Down 2.1%
NYSE COR opened at $341.05 on Friday. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.59. The firm's fifty day moving average price is $329.06 and its 200 day moving average price is $317.06. The company has a market capitalization of $65.08 billion, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 1.80 and a beta of 0.58. Cencora has a 12 month low of $244.82 and a 12 month high of $377.54.
Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. During the same period last year, the business earned $3.84 EPS. Cencora's revenue for the quarter was up 5.5% compared to the same quarter last year. On average, sell-side analysts expect that Cencora will post 19.58 earnings per share for the current fiscal year.
Cencora Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a $0.66 dividend. This is an increase from Cencora's previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, November 13th. Cencora's dividend payout ratio (DPR) is presently 14.73%.
Cencora Company Profile
(
Get Free Report)
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.